{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:23:21Z","timestamp":1793193801065,"version":"4.5.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>Hearing loss, affecting a significant portion of the global population, is prevented with peroxisome proliferator-activated receptor \u03b3 agonism. Understanding potential protective treatments is crucial for public health. We examine the effect of telmisartan, an antihypertensive drug and partial peroxisome proliferator-activated receptor \u03b3 agonist, on hearing loss in patients with hypertension.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method and results<\/jats:title><jats:p>This retrospective cohort analysis used data from the OMOP Common Data Model database, encompassing information from three tertiary institutions in South Korea. The study included a substantial sample size of 860,103 people diagnosed with hypertension. The study included individuals who had been medically diagnosed with hypertension and had been prescribed antihypertensive drugs, including telmisartan. The study design was established to evaluate the comparative effects of telmisartan and other hypertension medications on hearing loss. We used propensity score matching (PSM) to create a balanced cohort, reducing potential biases between the telmisartan and non-telmisartan groups. From the initial 860,103 patients with hypertension, a propensity score matched cohort was derived from 20,010 patients, with 2,193 in the telmisartan group. After PSM, lower incidence of total hearing loss was observed in the telmisartan group compared to the non-telmisartan group during the 3-year follow-up (0.5% vs. 1.5%, log-rank <jats:italic>p<\/jats:italic> = 0.005). In subgroup analysis, this study showed consistent results that lower incidence of total hearing loss was higher in the telmisartan group than in the non-telmisartan group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Telmisartan was associated with reducing certain types of hearing loss in patients with hypertension. Further research is needed to confirm these findings and understand the mechanisms.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1410389","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T04:50:24Z","timestamp":1724734224000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Association of the protective effect of telmisartan on hearing loss among patients with hypertension"],"prefix":"10.3389","volume":"15","author":[{"given":"Jung-Joon","family":"Cha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjin","family":"Yum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eung Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Chan","family":"Rah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euyhyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi Jung","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Jun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Won","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Joon","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2471\/BLT.13.128728","article-title":"The global burden of disabling hearing impairment: a call to action","volume":"92","author":"Olusanya","year":"2014","journal-title":"Bull World Health Organ."},{"key":"B2","volume-title":"World Report on Hearing","year":""},{"key":"B3","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/lary.24913","article-title":"The prevalence of hearing loss in South Korea: data from a population-based study","volume":"125","author":"Jun","year":"2015","journal-title":"Laryngoscope."},{"key":"B4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2471\/BLT.19.230367","article-title":"Hearing loss grades and the International classification of functioning, disability and health","volume":"97","author":"Olusanya","year":"2019","journal-title":"Bull World Health Organ."},{"key":"B5","doi-asserted-by":"publisher","first-page":"111191","DOI":"10.1016\/j.mad.2019.111191","article-title":"Increased oxidative stress, inflammation, and glutamate: Potential preventive and therapeutic targets for hearing disorders","volume":"185","author":"Prasad","year":"2020","journal-title":"Mech Ageing Dev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND)","year":"2008","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"ONTARGET","year":"2008","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0188596","DOI":"10.1371\/journal.pone.0188596","article-title":"Effects of peroxisome proliferator activated receptors (PPAR)-\u03b3 and -\u03b1 agonists on cochlear protection from oxidative stress","volume":"12","author":"Sekulic-Jablanovic","year":"2017","journal-title":"PLoS ONE."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3389\/fphar.2018.01103","article-title":"Pioglitazone represents an effective therapeutic target in preventing oxidative\/inflammatory cochlear damage induced by noise exposure","volume":"9","author":"Paciello","year":"2018","journal-title":"Front Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"12716","DOI":"10.3390\/ijms222312716","article-title":"Telmisartan attenuates kanamycin-induced ototoxicity in rats","volume":"22","author":"Lee","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/ajh\/hpae012","article-title":"Three-year cardiovascular outcomes of telmisartan in patients with hypertension: an electronic health record-based cohort study","volume":"37","author":"Yum","year":"2024","journal-title":"Am J Hypertens"},{"key":"B12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-2710.2011.01295.x","article-title":"Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes","volume":"37","author":"Suksomboon","year":"2012","journal-title":"J Clin Pharm Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e642","DOI":"10.1097\/MJT.0000000000000733","article-title":"Telmisartan improves insulin resistance: a meta-analysis","volume":"25","author":"Wang","year":"2018","journal-title":"Am J Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/hr.2009.131","article-title":"Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy","volume":"32","author":"Masuda","year":"2009","journal-title":"Hypertens Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1586\/ecp.10.141","article-title":"Telmisartan for the reduction of cardiovascular morbidity and mortality","volume":"4","author":"Verdecchia","year":"2011","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/hr.2010.67","article-title":"Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy","volume":"33","author":"Sukumaran","year":"2010","journal-title":"Hypertens Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/ajh\/hpt188","article-title":"Telmisartan reduces mortality and left ventricular hypertrophy with sympathoinhibition in rats with hypertension and heart failure","volume":"27","author":"Kishi","year":"2014","journal-title":"Am J Hypertens."},{"key":"B18","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension."},{"key":"B19","doi-asserted-by":"publisher","first-page":"108637","DOI":"10.1016\/j.heares.2022.108637","article-title":"Therapeutics for hearing preservation and improvement of patient outcomes in cochlear implantation-Progress and possibilities","volume":"426","author":"Gay","year":"2022","journal-title":"Hear Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"46065","DOI":"10.1074\/jbc.M403046200","article-title":"NOX3, a superoxide-generating NADPH oxidase of the inner ear","volume":"279","author":"B\u00e1nfi","year":"2004","journal-title":"J Biol Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3390\/antiox10081188","article-title":"Noise-induced cochlear damage involves PPAR down-regulation through the interplay between oxidative stress and inflammation","volume":"10","author":"Paciello","year":"2021","journal-title":"Antioxidants (Basel)."},{"key":"B22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1124\/pr.112.007278","article-title":"A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists","volume":"65","author":"Michel","year":"2013","journal-title":"Pharmacol Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000506796","article-title":"Telmisartan protects auditory hair cells from gentamicin-induced toxicity in vitro","volume":"25","author":"Cortada","year":"2020","journal-title":"Audiol Neurootol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1410389\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T04:50:27Z","timestamp":1724734227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1410389\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":23,"alternative-id":["10.3389\/fneur.2024.1410389"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1410389","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"article-number":"1410389"}}